Journal
ANNUAL REVIEW OF MEDICINE
Volume 60, Issue -, Pages 13-23Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev.med.59.110106.212434
Keywords
lung vascular development; pulmonary vasoregulation; endothelial cells; smooth muscle cells
Categories
Funding
- Thrasher Foundation
- National Institutes of Health [HL68702]
Ask authors/readers for more resources
Pulmonary arterial hypertension (PAH) is a severe disease with marked morbidity and mortality for which therapeutic strategies have been limited. Basic research in vascular biology has implicated endothelin-1 (ET-1) and its receptors (ETA and ETB) in diverse preclinical models of PAH, and ET-1 has been shown to contribute significantly to PAH in human patients. Despite the complexity of roles of the ET receptors in the development or reversal of PAH in the laboratory, the introduction of endothelin receptor antagonists (ETRAs) to clinical medicine has substantially expanded our therapeutic approach toward severe PAH. This article briefly reviews preclinical data and the current status of ETRAs in the clinical management of PAH.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available